Literature DB >> 16463401

In vitro regulation of serotonin transporter activity by protein kinase A and nicotinic acetylcholine receptors in the prefrontal cortex of rats.

Tammy L Awtry1, Julie G Frank, Linda L Werling.   

Abstract

We investigated the effect of in vitro exposure to nicotinic acetylcholine receptors (nAChRs), agonists, antagonists, and protein kinase A (PKA) modulators on the activity of the serotonin transporter (SERT) in prefrontocortical (PFC) synaptosomes. The plasma membrane SERT is an active transport mechanism specific for serotonin. Receptors and second messengers capable of altering transporter activity would be expected to have profound effects on serotonergic neurotransmission and on functions involving serotonergic input, such as cognition, anxiety, and mood. Our data suggest that activation of nAChRs, quite likely via PKA, increase the activity of the SERT in the PFC and, thereby, can alter 5-HT levels in a region important in the behavioral effects of nicotine and 5-HT. Nicotine at 4 microM increased [(3)H]5-HT uptake by 75%. Because the nAChR antagonists mecamylamine and dihydro-beta-erythrodine (DHbetaE) both decreased [(3)H]5-HT uptake into synaptosomes, it appeared that the SERT might be tonically activated by acetylcholine present within our synaptosomal preparations. Blocking PKA significantly decreased [(3)H]5-HT, while stimulation of PKA activity significantly increased the uptake. A 66% decrease compared with control was produced by 100 microM Rp-cAMP, and a 41% increase in 5-HT uptake over control was observed with 30 microM Sp-cAMPs. Furthermore, the enhancement in uptake produced by 4 microM nicotine was inhibited in a time-dependent fashion by preincubation with 10 microM Rp-cAMP. A better understanding of the influence of the cholinergic system and the receptors involved in the trafficking of SERT would help clarify the important relationship between the cholinergic and serotonergic systems and the role these systems play in behavior.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16463401     DOI: 10.1002/syn.20251

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  5 in total

Review 1.  Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters.

Authors:  Daniel P Bermingham; Randy D Blakely
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

2.  Fluoride related changes in behavioral outcomes may relate to increased serotonin.

Authors:  Fuxin Lu; Yan Zhang; Alpa Trivedi; Xianging Jiang; Dave Chandra; Jiaolin Zheng; Yukiko Nakano; Dawud Abduweli Uyghurturk; Rozita Jalai; Sirin Guner Onur; Ali Mentes; Pamela K DenBesten
Journal:  Physiol Behav       Date:  2019-03-20

3.  Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization.

Authors:  Ramakrishna Nirogi; Renny Abraham; Pradeep Jayarajan; Venkatesh Goura; Rajesh Kallepalli; Rajesh Babu Medapati; Jayaprakash Tadiparthi; Vinod Kumar Goyal; Santosh Kumar Pandey; Ramkumar Subramanian; Surendra Petlu; Jagadeesh Babu Thentu; Veera Raghava Chowdary Palacharla; Shankar Reddy Gagginapally; Abdul Rasheed Mohammed; Venkat Jasti
Journal:  Psychopharmacology (Berl)       Date:  2022-03-17       Impact factor: 4.530

4.  Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Susan Slade; Michael Johnson; Ann Petro; Kofi Horton; Paul Williams; Amir H Rezvani; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2008-10-17       Impact factor: 4.432

5.  Human serotonin transporter expression during megakaryocytic differentiation of MEG-01 cells.

Authors:  Gino Giannaccini; Laura Betti; Lionella Palego; Lara Schmid; Laura Fabbrini; Caterina Pelosini; Claudia Gargini; Ylenia Da Valle; Mario Lanza; Alessandro Marsili; Margherita Maffei; Ferruccio Santini; Paolo Vitti; Aldo Pinchera; Antonio Lucacchini
Journal:  Neurochem Res       Date:  2009-12-30       Impact factor: 3.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.